NUC-1031: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 73755261 |
| SCHEMBL ID | 17171316 |
| MeSH ID | M0593900 |
| Synonym |
|---|
| nuc-1031 |
| gtpl7389 |
| benzyl (2s)-2-[({[(2r,3s,5r)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy}(phenoxy)phosphoryl)amino]propanoate |
| SCHEMBL17171316 |
| Q27074149 |
| nhtkgyomicwfqz-bsmftprpsa-n |
| benzyl ((((2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-l-alaninate |
NUC-1031 combined with carboplatin is well tolerated in recurrent ovarian cancer.
| Excerpt | Reference | Relevance |
|---|---|---|
| " In PRO-002, NUC-1031 was combined with carboplatin in recurrent ovarian cancer." | ( A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Blagden, SP; Gabra, H; Ghazaly, E; Gnanaranjan, C; Harrison, DJ; Kazmi, F; McCracken, NW; Nicum, S; Roux, RL; Spiers, L; Sukumaran, A, 2021) | 1.25 |
| "NUC-1031 combined with carboplatin is well tolerated in recurrent ovarian cancer." | ( A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer. Blagden, SP; Gabra, H; Ghazaly, E; Gnanaranjan, C; Harrison, DJ; Kazmi, F; McCracken, NW; Nicum, S; Roux, RL; Spiers, L; Sukumaran, A, 2021) | 2.32 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.83) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||